Macro Technicals - 4 December 2017
Pfizer (PFE) set up for sharp directionnal move into year-end, 2018.Pfizer is a research-based biopharmaceutical company. The company is engaged in discovering, developing, manufacturing and distributing of healthcare products, including medicines and vaccines. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes Oncology, Inflammation and Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine business units, as well as a hospital business unit; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Celebrex, Viagra, and certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.
Global Market Research provide quantitative, algorithm-based research to institutional investors in the Equity, FX, Rate, Commodity and Blockchain markets. GMR provide significant value to our wide range of clients in four distinct ways:
- Translate broad Macro ideas into actionable Price Strategy;
- Apply the GMR proprietary method as an independent filter for client-driven ideas;
- Utilize GMR's unique algorithm to identify markets with potential for major price shock;
- Bespoke Analysis.
GMR regularly publish four specialized subscription reports: MACRO Technicals® focuses on the major USD crosses, US Treasury yields and Equity markets. GMR Weekly Notes® identifies a Top 10 list of risk/reward opportunities across asset classes. Petro-Technicals® covers Crude Oil and Natural Gas markets; Bitcoin Technicals® focuses on blockchain technology.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.